MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) shares gapped down prior to trading on Thursday . The stock had previously closed at $8.01, but opened at $7.60. MiMedx Group shares last traded at $8.01, with a volume of 89,438 shares changing hands.
Wall Street Analyst Weigh In
MDXG has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a research note on Thursday. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, MiMedx Group presently has an average rating of "Buy" and a consensus price target of $12.00.
Get Our Latest Analysis on MiMedx Group
MiMedx Group Stock Down 1.2 %
The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The stock has a market cap of $1.22 billion, a P/E ratio of 15.09 and a beta of 1.94. The firm has a 50-day simple moving average of $8.70 and a two-hundred day simple moving average of $7.73.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analysts' expectations of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities research analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in MDXG. IMG Wealth Management Inc. bought a new position in shares of MiMedx Group in the fourth quarter worth $28,000. Blue Trust Inc. bought a new position in shares of MiMedx Group in the third quarter worth $30,000. Virtus Fund Advisers LLC bought a new position in shares of MiMedx Group in the fourth quarter worth $35,000. Van ECK Associates Corp bought a new position in shares of MiMedx Group in the fourth quarter worth $40,000. Finally, Point72 DIFC Ltd increased its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock worth $45,000 after purchasing an additional 4,275 shares during the period. Institutional investors own 79.15% of the company's stock.
About MiMedx Group
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
